| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/20/2003 | WO2002064109A3 Mucoadhesive pharmaceutical formulations |
| 02/20/2003 | WO2002060406A3 Veterinary dermatologic composition |
| 02/20/2003 | WO2002053090A3 Medicinal association of a biguanine (metformin) and arginine |
| 02/20/2003 | WO2002047730A8 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 02/20/2003 | WO2002045738A3 Vaccine composition containing transforming growth factor alpha |
| 02/20/2003 | WO2002042295A3 Peptides as met-ap2 inhibitors |
| 02/20/2003 | WO2002024623A3 Novel alkanoic acid derivatives |
| 02/20/2003 | WO2002024158A8 Pulmonary delivery in treating disorders of the central nervous system |
| 02/20/2003 | WO2002019842A2 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 02/20/2003 | WO2002015940A3 Solution of an oxazolidinone antibiotic drug |
| 02/20/2003 | WO2002007780A3 Methods for identifying therapeutic targets |
| 02/20/2003 | WO2001056547B1 Preparation of aqueous clear solution dosage forms with bile acids |
| 02/20/2003 | US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| 02/20/2003 | US20030036568 Permeation enhancers |
| 02/20/2003 | US20030036563 Carboxyvinylpolymer neutralized as a gel-forming agent or a polyacrylamide-isoparaffin and ethanol, isopropanol or diethylene glycol monoethyl ether as a solvent |
| 02/20/2003 | US20030036538 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest. |
| 02/20/2003 | US20030036525 Hyaluronic acid and/or a salt thereof associated with/bound with an effective amount of anti-sense to the gene implicated in the disease or condition |
| 02/20/2003 | US20030036524 Transfecting with a polynucleotide that comprises a prodrug metabolising gene, and a promoter capable of selectively promoting the transcription of the prodrug metabolising gene in said endothelial cell; and delivering said prodrug |
| 02/20/2003 | US20030036518 Artificial polymeric membrane structure, method for preparing same, method for preparing this polymer, particle and film containing this structure |
| 02/20/2003 | US20030036172 Polypeptide for use in the treatment of cancerous, angiogenesis, inflammatory shock and autoimmune diseases |
| 02/20/2003 | US20030036171 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 02/20/2003 | US20030036170 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 02/20/2003 | US20030035853 Antiinflammatory agents, analgesics; fatty acid mixture and plant extracts |
| 02/20/2003 | US20030035850 Hemorrhoidal compositions and method of use |
| 02/20/2003 | US20030035845 Composition for sustained release of non-aggregated erythropoietin |
| 02/20/2003 | US20030035839 Multilayer tablets; side effect reduction |
| 02/20/2003 | US20030035838 Drug delivery system exhibiting permeability control |
| 02/20/2003 | US20030035837 Mixture of drug with retarder; sustained release |
| 02/20/2003 | US20030035836 Oral controlled release pharmaceutical composition for once-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases |
| 02/20/2003 | US20030035835 Protective overcoatings |
| 02/20/2003 | US20030035833 Solid drug in aqueous solutions; efferverscence |
| 02/20/2003 | US20030035832 Compression of drug and adjuvant |
| 02/20/2003 | US20030035831 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/20/2003 | US20030035829 Liposomal compositions for the delivery of nucleic acid catalysts |
| 02/20/2003 | US20030035828 Antiallergens; sustained release; transdermal administering |
| 02/20/2003 | US20030035827 Pharmaceutical compositions containing substrates of enabling enzymes to preferentially deliver drugs away from PBVC or GIC systems |
| 02/20/2003 | US20030035826 Water soluble active material and polymer mixture |
| 02/20/2003 | US20030035812 Administering vaccine |
| 02/20/2003 | US20030035804 In situ drug delivery |
| 02/20/2003 | US20030035802 Angiogenosis inhibitors; antitumor, anticancer agents |
| 02/20/2003 | US20030035787 Polyanhydrides with biologically active degradation products |
| 02/20/2003 | US20030035785 Skin protection composition |
| 02/20/2003 | US20030035774 Salt/ion pair medicinal aerosol formulation |
| 02/20/2003 | CA2701551A1 Polysaccharide-containing compositions and use thereof |
| 02/20/2003 | CA2457624A1 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | CA2457314A1 Percutaneous absorption preparations |
| 02/20/2003 | CA2456833A1 Polysaccharide-containing compositions and use thereof |
| 02/20/2003 | CA2456808A1 Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support |
| 02/20/2003 | CA2456802A1 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 02/20/2003 | CA2456723A1 Inhibitors of her3 activity |
| 02/20/2003 | CA2456706A1 Drug release system for controlled therapy |
| 02/20/2003 | CA2456328A1 Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof |
| 02/20/2003 | CA2456322A1 Compositions and methods to prevent abuse of opioids |
| 02/20/2003 | CA2456052A1 Surfactant compounds and uses thereof |
| 02/20/2003 | CA2455951A1 Bi-directional synthesis of oligoguanidine transport agents |
| 02/20/2003 | CA2455420A1 Compositions and methods to prevent abuse of opioids |
| 02/20/2003 | CA2454910A1 Erythrocytic cells and method for preserving cells |
| 02/20/2003 | CA2454684A1 Eukaryotic cells and method for preserving cells |
| 02/20/2003 | CA2454173A1 Stabilized oral suspension formulation |
| 02/20/2003 | CA2453245A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates |
| 02/20/2003 | CA2453214A1 Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy |
| 02/20/2003 | CA2419389A1 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 02/19/2003 | EP1284286A1 Alpha-isomaltosyltransferase, process for producing the same and use thereof |
| 02/19/2003 | EP1284151A1 Topical treatment of pain and to promote healing including capsaicin as an analgesic |
| 02/19/2003 | EP1284145A1 2-(3,4-Dihydroxyphenyl)ethyl substituted carbonic acid derivatives and their use |
| 02/19/2003 | EP1284143A1 A process for the preparation of pharmaceutical formulations containing lactoferrin description |
| 02/19/2003 | EP1284137A1 Nonoral preparation having three-layer structure |
| 02/19/2003 | EP1283871A2 Production of dendritic cells from bone-marrow stem cells |
| 02/19/2003 | EP1283854A1 Solutizing agents |
| 02/19/2003 | EP1283828A1 Novel polymorph v of torasemide |
| 02/19/2003 | EP1283726A2 Dendritic cells loaded with toxic substances |
| 02/19/2003 | EP1283725A1 Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof |
| 02/19/2003 | EP1283724A1 Systems and methods for topical treatment with nitric oxide |
| 02/19/2003 | EP1283718A2 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 02/19/2003 | EP1283710A1 Use of a celecoxib composition for fast pain relief |
| 02/19/2003 | EP1283705A1 Transdermal therapeutical system with a reduced tendency of the active substance to crystallize |
| 02/19/2003 | EP1283704A2 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents |
| 02/19/2003 | EP1283703A1 Rapidly disintegrating tablet and process for the manufacture thereof |
| 02/19/2003 | EP1283700A2 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 02/19/2003 | EP1283699A2 Preparation of injectable suspensions having improved injectability |
| 02/19/2003 | EP1131327B1 Prostaglandin conjugates for treating or preventing bone diseases |
| 02/19/2003 | EP1066040B1 Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| 02/19/2003 | EP0793484B1 Adjuvant for a vaccine composition |
| 02/19/2003 | EP0777485B1 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof |
| 02/19/2003 | EP0729363B1 Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors |
| 02/19/2003 | CN1398188A Boltuminum toxin pharmaceutical compsns |
| 02/19/2003 | CN1398185A Method to potentiate therapueutic efficiency of taxane and derivatives thereof |
| 02/19/2003 | CN1398184A Compsns. contg. itraconazole with improved bioavailability and narrow intra-and inter-individual variation of its absorption |
| 02/19/2003 | CN1397348A Novel target compsn. for diagnosis and treatment |
| 02/19/2003 | CN1397284A Embedded nusk and its preparing process |
| 02/19/2003 | CN1101679C Pharmaceutical formulations of highly lipophilic camptothecin derivatives |
| 02/19/2003 | CN1101677C Pharmaceutical injection solution contg. taxol |
| 02/19/2003 | CN1101675C Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| 02/18/2003 | US6521746 Leukotoxin polypeptide fused to gonadotropin releasing hormone/factor multimer; increased immunogenicity |
| 02/18/2003 | US6521736 Amphiphilic polymeric materials |
| 02/18/2003 | US6521639 Donepezil hydrochloride and lactate of a higher alcohol; increased absorption |
| 02/18/2003 | US6521599 Carrier comprises glycine and aqueous hydrochloric acid; compatability; neutralization |
| 02/18/2003 | US6521597 Water soluble polysaccharide mixed with luteinizing hormone releasing hormone analogues; bioavailability; chemically stability; longer useful shelf life |
| 02/18/2003 | US6521456 Gene therapy for cancer; treating viral infections, nervous system disorders, graft rejection, and monogenic or polygenic disorders |
| 02/18/2003 | US6521265 Mixing anhydrous ferrate (VI) salt which hydrates to produce Fe+3 with blood flowing from a wound or water to form a paste; applying paste to the wound; K2FeO4 becomes FeOOH in water, which upon drying, yields ultrafine Fe2O3 |